Therapiesteuerung der COPD durch eosinophile Granulozyten?

Helgo Magnussen

doi:10.1055/a-0748-8856

DMW - Deutsche Medizinische Wochenschrift, Table of Contents

Dtsch Med Wochenschr 2019; 144(13): 917-921
DOI: 10.1055/a-0748-8856

Standpunkt

Therapiesteuerung der COPD durch eosinophile Granulozyten?

Ansätze zur personalisierten Medizin bei obstruktiven Atemwegserkrankungen Therapy control of COPD by Eosinophilic Granulocytes?

Helgo Magnussen

Abstract

Symptomatic patients with COPD reporting about repeated exacerbations in their history (group D according to GOLD recommendations) are treated with dual bronchodilation (LAMA/LABA) with potential benefits from additional ICS. Eosinophils in peripheral blood are considered as potential biomarkers to predict exacerbations. > 300 cells/µL or 4 % of eosinophils in peripheral blood are recommended to treat the patients with additional ICS. In clinical practice, about 10 – 15 % of patients with COPD are classified as group D according to GOLD. < 20 % have increased eosinophils in peripheral blood. Thus, ICS therapy should be restricted to a minority of patients with COPD

Schwerpunkt der medikamentösen Therapie der symptomatischen COPD sind langwirksame Anticholinergika (LAMA) und langwirksame β₂-Symphatikomimetika (LABA). Zusätzlich können bei symptomatischen Patienten mit gehäuften Exazerbationen inhalative Kortikosteroide hilfreich sein. Welche Patienten darauf ansprechen, lässt sich möglicherweise mithilfe einer erhöhten Eosinophilen-Zahl im peripheren Blut vorhersagen.

Schlüsselwörter

COPD - inhalative Kortikosteroide (ICS) - eosinophile Granulozyten

Key words

COPD - inhaled corticosteroids - eosinophils

Full Text

References

Literatur
1 Vogelmeier C, Buhl R, Burghuber O. et al. Guideline for the Diagnosis and Treatment of COPD Patients – Issued by the German Respiratory Society and the German Atemwegsliga in Cooperation with the Austrian Society of Pneumology. Pneumologie 2018; 72: 253-308
2 Vogelmeier C, Criner GJ, Martinez FJ. et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. Am J Respir Crit Care Med 2017; 195: 557-582
3 Global Strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2019 report. https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.5-FINAL-04Nov2018_WMS.pdf . Accessed February 28, 2019.
4 Graf J, Jörres R, Lucke T. et al. Medikamentöse Therapie der COPD. Deutsches Ärzteblatt 2018; 37: 599-605
5 Calverley P, Anderson J, Celli B. et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 22: 775-789
6 Wedzicha J, Calverley P, Seemungal T. et al. The prevention of Chronic Obstructive Pulmonary Disease exacerbations by Salmeterol/Fluticasone propionate or Tiotropium bromide. Am J Respir Crit Care Med 2008; 177: 19-26
7 Suissa S, Patenaude V, Lapi F. et al. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax 2013; 68: 1029-1036
8 Brusselle G, Pavord I, Landis S. et al. Blood eosinophil levels as a biomarker in COPD. Respir Med 2018; 138: 21-31
9 Agusti A, Fabbri L, Singh D. et al. Inhaled corticosteroids in COPD: Friend or foe?. Eur Respir J 2018;
10 Papi A, Vestbo J, Fabbri L. et al. Extrafine inhaled Tripel therapy versus dual bronchodilator therapy in Chronic Obstructive Pulmonary Disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet 2018; 391: 1076-1084
11 Lipson D, Barnhart F, Brealey N. et al. Once-daily single inhaler Tripel versus dual therapy in patients with COPD. N Engl J Med 2018; 378: 1671-1680
12 Magnussen H, Disse B, Rodriguez-Roisin R. et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med 2014; 371: 1285-1294
13 Chapman K, Hurst J, Frent S. et al. Long-Term Tripel Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Tripel-Dummy Clinical Trial. Am J Respir Crit Care Med 2018; 198: 329-339
14 Wedzicha J, Banerji D, Chapman K. et al. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med 2016; 374: 2222-2234
15 Watz H, Tetzlaff K, Wouters EF. et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med 2016; 4: 390-398
16 Calverley P, Tetzlaff K, Vogelmeier C. et al. Eosinophilia, frequent exacerbations, and steroid response in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2017; 196: 1219-1221
17 Buhl R, Criée C, Kardos P. et al. Dual bronchodilation vs Tripel therapy in the “real-life” COPD DACCORD study. Int J Chron Obstruct Pulmon Dis 2018; 13: 2557-2558
18 Suissa S, Dell’Aniello S, Ernst P. Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study. Lancet Respir Med 2018; 6: 855-862
19 Yun J, Lamb A, Chase R. et al. Blood eosinophil count thresholds and exacerbations in patients with Chronic Obstructive Pulmonary Disease. J Allergy Clin Immunol 2018; 141: 2037-2047
20 Brusselle G, Price D, Gruffydd-Jones K. et al. The inevitable drift to Tripel therapy in COPD: an analysis of prescribing pathways in the UK. International Journal of COPD 2015; 10: 2207-2217